DMDivya Mohan

Divya Mohan

*This is an algorithmically generated author record based on publicly available information.

Divya Mohan has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial

    by Divya Mohan, Holly R. Keir, Hollian Richardson, David Mayhew, Joseph Boyer, Marc P. van der Schee, Max D. Allsworth, Bruce E. Miller, Ruth Tal-Singer, James D. Chalmers

    Background: Breath analysis is a burgeoning field, with interest in volatile organic compounds (VOCs) as a noninvasive diagnostic tool or an outcome measure, but no randomised controlled trials (RCTs) have yet evaluated this technology in a clinical trial longitudinally. In a pilot RCT, our exploratory objectives were feasibility of measuring VOCsviamultiple techniques, assessing relationships between VOCs andHaemophiluscolonisation and whether CXCR2 antagonism with danirixin altered lung microbiome composition in individuals with COPD.Method: 43 participants had VOCs and sputum biomarkers evaluated. VOCs and induced sputum were collected after 6 h of fasting at screening and at days 1, 7 and 14. VOCs were analysedviagas chromatography mass spectrometry (GC-MS), field asymmetric ion mobility spectrometry (FAIMS) and eNose. The primary outcome for these analyses was the relationship between VOCs andHaemophilusabundance determined by 16S rRNA sequencing.Results: A joint-effects model demonstrated a modest relationship between four exhaled VOCs andHaemophilusrelative abundance (R2=0.55) measured only by GC-MS, but not as measured using gas chromtaography FAIMS or eNose. There was considerable variability in absolute quantities of individual VOCs longitudinally.Conclusions: VOC measurement in clinical trials to identify subsets of COPD is feasible, but assessment of new VOC technologies must include concurrent GC-MS validation. Further work to standardise collection of VOCs and measuring a background or “housekeeper” VOC is required to understand and normalise individual VOC quantities.


  • Open Access

    Quantitative18F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD

    by Laurence Vass, Marie Fisk, Joseph Cheriyan, Divya Mohan, Julia Forman, Adelola Oseni, Anand Devaraj, Kaisa M. Mäki-Petäjä, Carmel M. McEniery, Jonathan Fuld, et al.

    Rationale: COPD and smoking are characterised by pulmonary inflammation.18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging may improve knowledge of pulmonary inflammation in COPD patients and aid early development of novel therapies as an imaging biomarker.Objectives: To evaluate pulmonary inflammation, assessed by FDG uptake, in whole and regional lung in “usual” (smoking-related) COPD patients, alpha-1 antitrypsin deficiency (α1ATD) COPD patients, smokers without COPD and never-smokers using FDG PET/CT. Secondly, to explore cross-sectional associations between FDG PET/CT and systemic inflammatory markers in COPD patients and repeatability of the technique in COPD patients.Methods: Data from two imaging studies were evaluated. Pulmonary FDG uptake (normalised Ki; nKi) was measured by Patlak graphical analysis in four subject groups: 84 COPD patients, 11 α1ATD-COPD patients, 12 smokers and 10 never-smokers. Within the COPD group, associations between nKiand systemic markers of inflammation were assessed. Repeatability was evaluated in 32 COPD patients comparing nKivalues at baseline and at 4-month follow-up.Results: COPD patients, α1ATD-COPD patients and smokers had increased whole lung FDG uptake (nKi) compared with never-smokers (0.0037±0.001, 0.0040±0.001, 0.0040±0.001versus0.0028±0.001 mL·cm−3·min−1, respectively, pi(β=0.30, p=0.02) in multivariate analysis adjusted for current smoking, forced expiratory volume in 1 s % predicted, systemic neutrophils and C-reactive protein levels. Mean percentage difference in nKibetween the baseline and follow-up was 3.2%, and the within subject coefficient of variability was 7.7%.Conclusions: FDG PET/CT has potential as a noninvasive tool to enable whole lung and regional quantification of FDG uptake to assess smoking- and COPD-related pulmonary inflammation.


  • Open Access

    Gastric dilatation and volvulus (bloat) - A case report and mini review of literature

    by Kalaiselvan Elangovan, Shivaraju Shivaramu, Swapan K. Maiti, Sunil K.S. Padmanabha, Divya Mohan

    Gastric dilatation and volvulus (GDV) is a progressing bloat condition in dogs characterized as dilatation followed by rotation of stomach. A sevenyear old 18 kg black colour female non-descriptive dog presented, with history of difficulty in respiration within half an hour after feeding of curd meals. With the history and general clinical examination the case tentatively diagnosed as gastric dilatation. After unsuccessful advancement of oro-gastric tube, needle gastric paracentesis was performed on left side of the abdomen caudal to the last rib for decompression. Mid-ventral celiotomy and gastrotomy were performed after stabilization of heart rate and respiratory rate. After evacuating the whitish frothy content from the stomach, derotation and incisional gastropexy was performed. On 14thpostoperative day telecommunication confirmed the milk based meal induced GDV canine patient recovered uneventfully. Electrocardiogram monitoring done for first 24 hours period and ventricular arrhythmia was managed by using lidocaine (loading@2mg/ kg bw followed by 25mcg/kg/min for 30 min). It is concluded that on 14th postoperative day telecommunication confirmed the milk based meal induced GDV canine patient recovered uneventfully.

  • Open Access

    The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial

    by Marie Fisk, Joseph Cheriyan, Divya Mohan, Julia Forman, Kaisa M Mäki-Petäjä, Carmel M McEniery, Jonathan Fuld, James H F Rudd, Nicholas S Hopkinson, David A Lomas, et al.

    Cardiovascular disease is a major cause of morbidity and mortality in COPD patients. Systemic inflammation associated with COPD, is often hypothesised as a causal factor. p38 mitogen-activated protein kinases play a key role in the inflammatory pathogenesis of COPD and atherosclerosis. This study sought to evaluate the effects of losmapimod, a p38 mitogen-activated protein kinase (MAPK) inhibitor, on vascular inflammation and endothelial function in chronic obstructive pulmonary disease (COPD) patients with systemic inflammation (defined by plasma fibrinogen >2·8g/l). This was a randomised, double-blind, placebo-controlled, Phase II trial that recruited COPD patients with plasma fibrinogen >2.8g/l. Participants were randomly assigned by an online program to losmapimod 7·5mg or placebo tablets twice daily for 16 weeks. Pre- and post-dose 18F-Fluorodeoxyglucose positron emission tomography co-registered with computed tomography (FDG PET/CT) imaging of the aorta and carotid arteries was performed to quantify arterial inflammation, defined by the tissue-to-blood ratio (TBR) from scan images. Endothelial function was assessed by brachial artery flow-mediated dilatation (FMD). We screened 160 patients, of whom, 36 and 37 were randomised to losmapimod or placebo. The treatment effect of losmapimod compared to placebo was not significant, at -0·05 for TBR (95% CI: -0·17, 0·07), p = 0·42, and +0·40% for FMD (95% CI: -1·66, 2·47), p = 0·70. The frequency of adverse events reported was similar in both treatment groups. In this plasma fibrinogen-enriched study, losmapimod had no effect on arterial inflammation and endothelial function at 16 weeks of treatment, although it was well tolerated with no significant safety concerns. These findings do not support the concept that losmapimod is an effective treatment for the adverse cardiovascular manifestations of COPD.


  • Open Access

    P94 Cardiorespiratory physiology in patients with copd according to blood eosinophilia: data from the erica cohort

    by L Buss, TM McKeever, D Mohan, K Maki-Petaja, J Forman, CM McEniery, J Cheryian, N Gale, Jr Cockcroft, Pm Calverley, et al.

    Introduction Blood eosinophils level in Chronic Obstructive Pulmonary Disease (COPD) is a candidate biomarker for Regulatory qualification as a drug development tool identifying individuals who may benefit from targeted therapies. Current evidence focused on association with exacerbations and response to therapy, however the association of eosinophilia with cardiorespiratory physiology has not been determined. Methods The ERICA (Evaluating the Role of Inflammation in Chronic Airway Disease) study is a large multicentre study of patients with COPD.1 Aortic pulse wave velocity (PWV), carotid intimal thickness (CIMT) and spirometry were measured. Health Status (CAT) was recorded. From the full blood count, both absolute and percentage eosinophil counts were considered. We used previously validated cut offs2 of 0.3 × 109 cells/L and 2% to compare aortic PWV, CIMT and spirometry variables using a Student’s t-test. A multivariate model was then built to examine the effect after adjusting for confounding factors. Results 519 subjects were included in this analysis. Of these, 58% were men, mean (SD) age of 66.9 (7.6) years with a median smoking history of 42 pack years. Mean (SD) resting heart rate was 75 (13)bpm, mean arterial pressure 104 (12) mmHg and percentage predicted FEV152.5 (16.1)%. When comparing high and low eosinophil groups at both 0.3 × 109 cells/L and 2% cut-offs there was no difference in smoking status or pack years, spirometry variables or CAT score. There was no difference in prevalence of ischaemic heart disease, stroke or diabetes. Aortic PWV or CIMT were not different between groups. Multiple regression confirmed this (Table). Conclusions A phenotype defined by blood eosinophilia does not relate to cardiorespiratory physiological variables in subjects with COPD. References Mohan Det al. Journal of COPD2015. Negewo Net al. Respirology2017.

  • Late Breaking Abstract - Co-morbid disease clusters in chronic obstructive pulmonary disease: the ERICA study

    by Divya Mohan, Matthew Allinder, Julia Forman, Carmel Mceniery, Charlotte Bolton, John Cockcroft, William Macnee, Jonathan Fuld, Nichola Gale, Marie Fisk, et al.

    Background: Comorbidities are common in Chronic Obstructive Pulmonary Disease (COPD), related to heterogeneity, morbidity and mortality. We aimed to identify disease clusters to examine overlap of extra-pulmonary manifestations in COPD. Methods: 729 GOLD II–IV COPD subjects underwent multiple phenotypic assessments, including aortic pulse wave velocity (aPWV) and isometric quadriceps strength, in a prospective, observational study. Baseline data was subject to k-means cluster analysis. Results: Four phenotypic clusters emerged: subjects with systemic inflammation, moderate airflow obstruction and frequent exacerbations (cluster 1), subjects without systemic inflammation but severe airflow obstruction (cluster 2), subjects with moderate airflow obstruction and vascular comorbidities (cluster 3) and fewer comorbidities (cluster 4). Elevated aPWV and muscle weakness were present across clusters 1, 2 and 3, yet functional and patient reported measures were worst within clusters 1 and 3. Conclusions: Distinct clusters of COPD identified in the ERICA cohort demonstrated that airflow limitation alone cannot predict the presence of extrapulmonary manifestations, vascular risks or functional limitation. ERICA was funded by a grant from Innovate UK and contributions in kind from GSK.

  • LATE-BREAKING ABSTRACT: Cardiovascular and skeletal muscle manifestations in COPD: The ERICA study

    by Divya Mohan, Michael Polkey, Julia Forman, Carmel McEniery, Charlotte Bolton, John Cockcroft, Jonathan Fuld, Mellone Marchong, Nichola Gale, Marie Fisk, et al.

    Rationale Elevated cardiovascular risk (CV) and skeletal muscle dysfunction (SM) are two of the most important extra-pulmonary manifestations in COPD. Our aim was to determine whether aortic pulse wave velocity (aPWV) and skeletal muscle weakness, as measures of CV and SM respectively, are linked in COPD. Methods 729 GOLD II–IV COPD subjects underwent multiple phenotypic assessments. We defined elevated aPWV as >10m/s (Reference Values for Arterial Stiffness 2010) and quadriceps weakness by a gender-specific equation for quadriceps maximal volitional contraction (QMVC) (Seymour et al 2010). Results CV and SM were present in 46.3% and 43.6% of our cohort respectively. 21.4% of subjects exhibited both CV and SM, similar to the overlap predicted by chance alone (20.2%). Presence of SM was associated with more adverse measures (table 1). | | Overall (n=729) | Neither SM/CV (n=194) | SM only (n=137) | CV only (n=154) | Both CV&SM (n=132) | || | Age(yrs) | 67(8) | 66(7)** | 63(8)\***| | 70(7)\***| | 70(7)\***| | | Gender(%male) | 61 | 58 | 55 | 68 | 63 | | BMI(kg/m2) | 27.3(5.8) | 26.3(4.9)** | 26.9(5.6) | 27.1(4.9) | 28.3(6.5)* | | FEV1(% pred) | 52.2(16.1) | 57.4(14.2)\***| | 49.4(16.3)* | 51.8(16.4) | 50.5(15.8) | | QMVC(%pred) | 68(21) | 81(15) | 52(12) | 82(15) | 50(13) | | 6MWD(m) | 345(130) | 404(104)\***| | 338(129) | 361(125) | 282(132)\***| | | APWV(m/s) | 10.3(2.6) | 8.3(1.1) | 8.3(1.1) | 12.2(2.0) | 12.7(1.9) | | Fibrinogen(g/L) | 3.5(0.9) | 3.4(1.0) | 3.4(0.8) | 3.5(0.8) | 3.5(0.9) | | SGRQ score | 51.4(22.3) | 44.2(21.2)\***| | 57.4(21.5)** | 47.7(22.5)* | 55.8(20.5)* | | Exacerbations/year | 1.9(2.1) | 1.7(1.8) | 2.2(2.0) | 1.8(2.3) | 2.2(2.3) | * Values expressed as mean(SD) TABLE 1: Baseline demographics Conclusions CV and SM are prevalent and distinct manifestations in COPD. The presence of SM is associated with worse functional and patient reported outcomes than presence of CV alone.

  • P7.14 SERUM INFLAMMATORY MARKERS ARE POOR PREDICTORS OF VASCULAR INFLAMMATION AND VASCULAR INFLAMMATION DOES NOT DETERMINE AORTIC STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    by Marie Fisk, Divya Mohan, Joseph Cheriyan, Julia Forman, Carmel M. McEniery, John R. Cockcroft, Ruth Tal-Singer, Michael I. Polkey, Ian B. Wilkinson

  • 1.6 THE BODE INDEX PROGNOSTIC SCORE IS AN INDEPENDENT DETERMINANT OF ARTERIAL STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    by Marie Fisk, Nichola Gale, Divya Mohan, Carmel M. McEniery, Julia Forman, Charlotte E. Bolton, William MacNee, John R. Cockcroft, Joseph Cheriyan, Ruth Tal-Singer, et al.


  • Open Access

    P129 Skeletal muscle weakness, not arterial stiffness, differs according to GOLD group in COPD

    by M Fisk, N Gale, D Mohan, Mn Marchong, J Forman, DA Lomas, Jr Cockcroft, Ce Bolton, W MacNee, J Fuld, et al.

    Introduction In the GOLD 2011 COPD classification, patients in Group D are considered to be at highest risk of mortality, due to airflow limitation and exacerbations and also to be most symptomatic. Skeletal muscle weakness and cardiovascular disease are associated with mortality in patients with COPD and elderly people per se .We hypothesised that GOLD D patients would have more severe extra-pulmonary manifestations of COPD than A-C. Objectives To measure skeletal muscle weakness and arterial stiffness (an independent predictor of cardiovascular risk) in the ERICA (Evaluating the Role of Inflammation in Chronic Airways Disease) consortium (work package 1) cohort categorised by GOLD Group (ABCD). Methods ERICA is a multicentre UK study investigating the role of inflammation and the prevalence and significance of cardiovascular and skeletal muscle manifestations in COPD. This interim analysis was conducted on 395 (49%) of 800 planned participants. Measurements include aortic pulse wave velocity (APWV) to measure arterial stiffness, quadriceps maximal voluntary contraction force (QMVC), plasma fibrinogen and 6-minute walk distance (6MWD). We defined arterial stiffness as APWV >10m/s, and skeletal muscle weakness as QMVC/BMI (Body Mass Index) ratio >1.2. Results 395 subjects were classified according to GOLD groups using the mMRC (modified Medical Research Council) dyspnoea scale to evaluate symptoms, ( Table 1 ). The majority of subjects were in groups D (57%) and B (33%), with low numbers observed in groups A (6%) and C (4%). Higher levels of airflow limitation were observed in groups C & D (p = 0.012). Fibrinogen was higher in groups C & D (p = 0.001), consistent with COPD severity. Results are mean values (SD), except for gender. For 1-way ANOVA, pConclusion The GOLD group classification captures risk related to skeletal muscle weakness but not arterial stiffness and indicates groups B & D may benefit from intensive exercise therapy.